Molecular characteristics of atopic dermatitis patients with clinical remission

IF 3.9 2区医学 Q2 ALLERGY

World Allergy Organization Journal Pub Date : 2024-11-01 DOI:10.1016/j.waojou.2024.100983

Andrés Sánchez Biol, MSc, PhD(c) , Ana Caraballo MD , Leidy Alvarez MD, MSc, PhD(c) , Oscar Valencia MD , María-Nelly Restrepo MD , Rodrigo Gaviria MD , Margarita Velasquez-Lopera MD, PhD , Juan-Ricardo Urrego QFB, PhD , Jorge Sánchez MD, MSc, PhD

{"title":"Molecular characteristics of atopic dermatitis patients with clinical remission","authors":"Andrés Sánchez Biol, MSc, PhD(c) , Ana Caraballo MD , Leidy Alvarez MD, MSc, PhD(c) , Oscar Valencia MD , María-Nelly Restrepo MD , Rodrigo Gaviria MD , Margarita Velasquez-Lopera MD, PhD , Juan-Ricardo Urrego QFB, PhD , Jorge Sánchez MD, MSc, PhD","doi":"10.1016/j.waojou.2024.100983","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Atopic dermatitis (AD) is a frequent disease in infants with diverse clinical evolution. Although multiple studies have assessed inflammatory changes in chronic AD, little is known about the molecular transition from symptomatic stage to clinical remission without pharmacotherapy.</div></div><div><h3>Objective</h3><div>The aim of the study was to evaluate clinical and inflammatory factors and its relationship with AD clinical evolution.</div></div><div><h3>Methods</h3><div>Three groups of participants older than 10 years of age were recruited; 2 AD groups and 1 non-AD group. The AD-remission group (more than 1 year without AD symptoms and without pharmacotherapy), the AD-persistent group (AD symptoms and pharmacotherapy), and 1 non-AD group. We measured eosinophil peroxidase (EPX), eosinophil cationic protein (ECP), IgE autoantibodies against these antigens, and natural moisturizing factor (NMF).</div></div><div><h3>Results</h3><div>Different inflammatory profiles within each group were observed: AD-persistent group is characterized by a high frequency of IgE autoantibodies (55.5%), contrasting with the low occurrence in the non-AD group (2%) and a moderate frequency in the AD-remission group (21.4%). A similar distribution was observed for the other type 2 inflammatory biomarkers (Eosinophils, total IgE, EPX, ECP) and NMF.</div></div><div><h3>Conclusion</h3><div>Patients with AD-remission maintain a minimal T2 inflammation. We identified different potential biomarkers for prognosis of AD evolution. Further studies are necessary to evaluate the mechanisms that allow the coexistence of the inflammatory process without clinical symptoms.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"17 11","pages":"Article 100983"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Allergy Organization Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1939455124001157","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Atopic dermatitis (AD) is a frequent disease in infants with diverse clinical evolution. Although multiple studies have assessed inflammatory changes in chronic AD, little is known about the molecular transition from symptomatic stage to clinical remission without pharmacotherapy.

Objective

The aim of the study was to evaluate clinical and inflammatory factors and its relationship with AD clinical evolution.

Methods

Three groups of participants older than 10 years of age were recruited; 2 AD groups and 1 non-AD group. The AD-remission group (more than 1 year without AD symptoms and without pharmacotherapy), the AD-persistent group (AD symptoms and pharmacotherapy), and 1 non-AD group. We measured eosinophil peroxidase (EPX), eosinophil cationic protein (ECP), IgE autoantibodies against these antigens, and natural moisturizing factor (NMF).

Results

Different inflammatory profiles within each group were observed: AD-persistent group is characterized by a high frequency of IgE autoantibodies (55.5%), contrasting with the low occurrence in the non-AD group (2%) and a moderate frequency in the AD-remission group (21.4%). A similar distribution was observed for the other type 2 inflammatory biomarkers (Eosinophils, total IgE, EPX, ECP) and NMF.

Conclusion

Patients with AD-remission maintain a minimal T2 inflammation. We identified different potential biomarkers for prognosis of AD evolution. Further studies are necessary to evaluate the mechanisms that allow the coexistence of the inflammatory process without clinical symptoms.

Abstract Image

查看原文本刊更多论文

临床缓解的特应性皮炎患者的分子特征

导言特应性皮炎（AD）是婴儿的一种常见病，其临床演变多种多样。本研究旨在评估临床和炎症因素及其与 AD 临床演变的关系。方法招募了三组 10 岁以上的参与者：2 组 AD 组和 1 组非 AD 组。AD缓解组（1年以上无AD症状且未接受药物治疗）、AD持续组（有AD症状且接受药物治疗）和1个非AD组。我们测量了嗜酸性粒细胞过氧化物酶（EPX）、嗜酸性粒细胞阳离子蛋白（ECP）、针对这些抗原的 IgE 自身抗体以及天然保湿因子（NMF）：AD 持续组的特点是 IgE 自身抗体出现频率高（55.5%），而非 AD 组出现频率低（2%），AD 缓解组出现频率适中（21.4%）。其他第二类炎症生物标志物（嗜酸性粒细胞、总 IgE、EPX、ECP）和 NMF 的分布情况与此类似。我们发现了不同的潜在生物标志物，可用于预测 AD 的演变。有必要开展进一步的研究，以评估在无临床症状的情况下并存炎症过程的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Allergy Organization Journal Immunology and Microbiology-Immunology

CiteScore

9.10

自引率

5.90%

发文量

审稿时长

9 weeks

期刊介绍： The official pubication of the World Allergy Organization, the World Allergy Organization Journal (WAOjournal) publishes original mechanistic, translational, and clinical research on the topics of allergy, asthma, anaphylaxis, and clincial immunology, as well as reviews, guidelines, and position papers that contribute to the improvement of patient care. WAOjournal publishes research on the growth of allergy prevalence within the scope of single countries, country comparisons, and practical global issues and regulations, or threats to the allergy specialty. The Journal invites the submissions of all authors interested in publishing on current global problems in allergy, asthma, anaphylaxis, and immunology. Of particular interest are the immunological consequences of climate change and the subsequent systematic transformations in food habits and their consequences for the allergy/immunology discipline.